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COMMENTARY
Should hematopoietic growth factors 
routinely be given concurrently with 
cytotoxic chemotherapy?
Alexandra J. Croockewit, MD, Peter P. Koopmans, MD, and Ben E. de Pauw, MD
"y
Recombinant human (rh) hematopoietic gr
as gr a n u 1 o cy t e - m a c r  o p h #Cfactors (HGFs),
colony-stimulating factor (GM-CSF) and gri 
cyte colony-stimulating factor (G-CSF), have 
shown to accelerate significantly neutrophil recovery 
after conventional and high-dose chemotherapy or
Furthermore, the effects of HGFs are 
not restricted to the induction of proliferation, but
: effects on differentiation, priming of the
in neutrophils, as well as cn- 
agocytosis and other cellular functions."h
More than 25 years ago it was shown in patients 
undergoing therapy for leukemia that e was a
correlation 
tions and the duration and severity of
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Consequently, it was hypothesized that the use of 
HGFs would result in a decrease of the incidence of
enia on
allow more optimal dosing 
of cytotoxic chemotherapy. Trials to explore the latter 
question are still investigational. This commentary ad­
dresses the influence of HGFs, given as primary pro­
phylaxis, on the reduction of incidence of infections in 
patients with
the basis of both phase II and III studies that have 
appeared in the literature. The number of days with 
fever, number of febrile neutropenic clays, use of an­
tibiotics, the number of documented infections, and 
the duration of hospitalization were analyzed as pa­
rameters of putative efficacy. In several phase II stud­
ies the incidence of infections in patients treated with
with
but the value of such observations is limited 
because the supportive care, including the use of antibi­
otic agents, has changed considerably over time.
ADMINISTRATION OF HGF AFTER 
STANDARD-DOSE CHEMOTHERAPY
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Table I. Influence of H G F administration after conventional/dose chemotherapy on the infection rate in 
phase III placebo/controlled trials
Reduction in HGF/placebo groups of
n
Author
(HGF/
placebo) Disease
Cytotoxic
regimen
ANC <1000/ijJ
No. of days % of patients
Documented infections 
(% of patients)
G-CSF
Crawford et al.10 95/104 SCLC CDE Incomplete
datat
Incomplete
dataf
7/13
Kotake et al.11 32/38 Urogenital
cancer
M-VAC 1/7* Not given Not given
Trillet-Lenoir et ai.12 65/64 SCLC CDE 6/15 Not given 20/33
Pettengell et al.13
GM-CSF
41/39 NHL VAPEC-B Not given 37/85 * 17/13
Kaku et al.14 31/3.1 NHL CHOP Not given 52/73* 13/26
Gerhartz et al.15 91/91 NHL COP-BLAM Not given 19/33* 27/45§
de Vries et al.16 9/6 Ovarian
cancer
CAR, CTX Not given Significant
difference
Not given
HGF, Hematopoietic growth factors; ANC, absolute neutrophil count; G-CSF, granulocyte colony-stimulating factor; GM-CSF, granulocyte-macrophage CSF; 
CTX, cyclophosphamide; CAR, carboplatin; CDE, cyclophosphamide, doxorubicin, etoposide; CHOP, cyclophosphamide, doxorubicin, vincristine, prednisone; 
COP-BLAM, cyclophosphamide, doxorubicin, bleomycin, vincristin, procarbazine, prednisolone; M-VAC, methotrexate, vinblastin, doxorubicin, cisplatin; VAPEC-B, 
doxorubicin, cyclophosphamide, vincristine, bleomycine, etoposide, prednisolone; NHL, non-Hodgkin’s lymphoma; SCLC, small-cell lung cancer.
*Statistically significant difference (p <0.05) in favor of HGF; * ’"statistically significant difference (p <  0.05) in favor of control. 
tD a ta  only for first chemotherapy cycle.
£Fever defined as temperature >37.5° G
§Analysis for the subgroup receiving at least 70% of study medication.
Table II. Influence of HGF administration after autologous bone marrow transplantation on the infection 
rate in phase III placebo-controlled trials
Author
n
(HGF/pla cebo ) Disease
Reduction in
ANC >500/III
No. of days
HGF/placebo groups of
Documented infections 
( % of pa tien ts)
G-CSF
Gisselbrecht et al.20 163/152f Non-myeloid
cancer
14/20* 26/26
GM-CSF
Nemunaitis et al.17
'■fl É' %
65/63 Lymphoid
malignancies
19/26 * 17/30*
Link et al. 39/40 ALL, NHL 14/18* 46/70*
Advani et a l.l‘, 36/66 NHL, HD 12/16* 3/18 *
Bennett et al,21 27/22 HD 13/20 68/53
Gorin et al.*" 41/47 NHL 14/21 * 39/47
Advani et al. 231 $ NHL, HD, solid tumors 16/19 No sign i licanl d i He re nee
Rabinowe et al. 24/23 NHL 20/27* No
W.V.I
signi fi ca n t d i (Fe re nee
Khwaja et al.25 29/29 NHL, HD 14/20* 14/138
Gulati et al.2ft 12/12 HD Not given 17/8
HD, Hodgkin’s disease; NHL, non-Hodgkin’s lymphoma; SCLC, small-cell lung cancer.
•Statistically significant difference (p < 0,05) in favor of HGF.
t in  dudes patients undergoing allogeneic bone marrow transplantation.
$Total number of patients,
§Number of positive blood cultures.
in standard dosages have been published (Table I). 
In only one large study15 in patients treated with 
COP-BLAM polychemotherapy for non-Hodgkin’s 
lymphoma (consisting of cyclophosphamide, doxo­
rubicin, bleomycin, vincristine, procarbazine, and
in co
o f
number of days with fever and i
a c r *  4  i ' *  • *  V »  A  V
with a decreased 
ics. All other 
a decrease of
of
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Reduction in HGF/placebo groups of
-  I — . r | ,  r  I  ________
Fever (neutropenic) 
(% of patients)
• •*—« < *  a  ■ i  S  “  ' w . '  u h . i
Antibiotic use
No. of days
» S " V i  I
% of patients
40/77 * 1/2 per cycle Not given
Not given Not given 37/58
26/53 * Not given 37/58*
23/44 * $ Not given 22/31
13/2* * 
41/56§
Not given 
3/8 * §
Not given
Not given Not given Not given
Redua 
Fever (neu
.. « . . ■ r> .......««»>*> it .'>'•> . ■ . ■ . • ■ ...
No. o f days
'ion in HGF/pla 
trope nie)
% of patients
cebo groups of
Antibiotic use 
(No. of days)
3/5 * 66/70* 15/19*
8/8 97/97 ?4/?7*«m  r  i w  f
Not given 79/77 19/19
Not given Not given Not given
Not given Not given Not given
4/2 27/13 19/22
Not given Not given Not given
Not given No significant No significant
difference difference
8/6 Not given 8/3.5
Not given 100/100 Significant différence
other infection-related 
fever or the use of i
iters such as days 
ics, provided that data
10-14.1 ft
on
the discrepancy between effects on duration of gran-
nia and effects on documented infections 
is unknown but could be related to insufficient sta­
tistical power of the studies or to the individual 
characteristics of the patients and their underlying 
disease. Indeed, it should be emphasized that most 
chemotherapy schedules for nonleukemic disorders 
have been developed in an attempt to minimize the 
incidence and severity of neutropenia and are there­
fore rarely complicated by clinically or microbiolog- 
ically documented infections.
ADMINISTRATION OF HGF AFTER 
HIGH-DOSE CHEMOTHERAPY
The potential of HGF to reduce the incidence of 
infections can be assessed more adequately in the 
context of conditioning regimens for an autologous 
bone marrow transplantation (ABMT), inasmuch as 
ABMT usually results in relatively long periods of 
profound granulocytopenia. Moreover, a more reli­
able assessment of the incidence of infections can be 
made because the patients are hospitalized and are 
available for adequate daily monitoring, 
ingly, the results of studies concerning H G F admin­
istration in patients treated with high-dose therapy 
are almost as conflicting as those obtained in patients 
with less severe granulocytopenia. It can be postulated 
that a significant decrease of the incidence of docu-
convincing evidence for 
reduction of the incidence of infections attributable to 
accelerated neutrophil recovery. In light of this, only 
three phase III placebo-controlled studies in patients 
undergoing an ABM T,7‘iy showed a 
dence of documented infections in patients treated 
with HGF. Nemunaitis et al.17 reported that 65 pa­
tients with lymphoid malignancies who were receiving 
rhGM-CSF (250 mg/m2/day) after ABMT had statis­
tically significant fewer infections than 63 placebo-
versus 30%). Similarly, Link et
in f46%
treated with rhGM-CSF in comparison with 70% in
the group of patients treated with placebo. However,
:s on
findings (T<
phase III s
, a
ties, an enhanced tumor
in extramyeloid
se, or a
HGF.
Criteria used for the estimation of the presence of
infections in various trials 
and hospital stay—were not always irrefut 
rameters of i
#
C
otic treatment in 
granulocytic patie
27
icy to 
ies when fever occui s
ic
n t*
;r, fever can be due to many 
administration of rhGM -CSF
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possible relation to enhanced host de~ 
and other drugs. Some studies reported 
that the  duration of antibiotic treatment and hos­
pital stay were significantly shorter in the group of 
patients treated  with HGF. However, this is de­
batable as true evidence of infection because an ­
tibiotics were given mostly for fever only. The 
reason the  duration of use of antibiotics cannot be 
used as a parameter of infection is the correlation 
between duration of granulocytopenia and use of
s: in most st
il count (ANC)
%
to r
rose above 500 per microliter. 
ies9,17,14,22 H G F administration 
cost saving in the range of 25% to 35% in patients 
undergoing an ABMT.21' This was achieved mainly 
by reducing the duration of hospitalization, a ma­
jor cost factor in the management of neutropenia. 
Considering the possibility of the occurrence of an 
overwhelming infection in patients with profound 
granulocytopenia, most physicians will keep these 
patients hospitalized. Therefore the duration of a 
hospital stay is directly correlated with the pres­
ence o f  neutropenia, but it is questionable 
whether H G F  is truly saving cost, considering the 
fact that the incidence of documented infections 
was not reduced in the vast majority of studies. 
Improved diagnostic facilities to discriminate pa 
tients with an infection from those with a nonin-
s cause of fever, as well as better e
easy access to a hospital, may offer better
to
DISCUSSION
tions, remain i
v
that might be responsible 
clinical benefit and f t
in !A * t A J -4S
s that
clinical efficacy should be recognized. First, infee
if ter ABMT are 
the time period when ANC is < 
il.25 showed that 96% 
were isolated during the
v#** , Khwaja et
4c
ANC was
<100/(xl after ABMT and that HGFs have no major 
impact on the duration of the episode
1,1 K.25
i
but rathei
sis once it is initially established, causing a more 
rapid increase in the number of the neutrophils
after a period of severe neutropenia .  Second, pa­
tients trea ted  with chem otherapy and radiother­
apy are prone not only to infections as a result of 
granulocytopenia. N um erous o th e r  factors, such 
as those related to their underlying immunocom­
prom ised  state, the use of antibacterials and im­
munosuppressive drugs, the destruction  of physi­
cal barriers, and the use of indwelling intravascular
ance *  « : occur­
rence of mucositis is associated with both radiotherapy 
and chemotherapeutic regimens, particularly anthra-
>e cy-
tarabine.
There are no convincing data from the phase III
trials that decrease inci­
dence of gram-negative infections. On the other
hand, one should take into account that the use of 
prophylactic antibacterial agents has diminished 
and curtailed the incidence of  gram-negative in­
fections during neutropenia . T here fo re  the size of 
the trials done is probably too small to disclose a 
beneficial influence. In the trials o f  Nemunaitis et 
a l .17 and Link et a l . , IK the difference in infection 
rate was attributable to differences in infections 
caused by gram-positive bacteria. The number of 
fungal infections encoun te red  was too low to al­
low any conclusion, but in patients  with a high risk 
for fungal infections the use of  hematopoietic 
growth factors is attractive from a theoretical 
point o f  view. The risk for fungal infections in­
creases with prolonged neutropenia,•1CI and it is 
known that antifungal therapy is more effective 
after neutrophil recovery. Furtherm ore ,  in vitro
studies show that G-CSF po ten tia tes  anti-eandida 
growth inhibitory activity of polymorphonuclear
 ^I W “ I
cells. It must be concluded that, besides granu­
locytopenia, num erous factors de term ine  the risk 
of infection in patients trea ted  with chemotherapy 
and radiotherapy, for example, mucosal damage, 
central venous catheters, environm ent,  state a
)
kind of underlying disease, and supportive strate­
gies used. To allow a final assessment of the pu­
tative clinical benefit of HGFs, further data on 
hard end points such as docum en ted  infection are 
ultimately required. This w arran ts  carefully de­
signed randomized clinical trials that have tt 
balanced with respect to the major risk factors, 
which may necessitate stratification, particularly if 
the num ber of patients to be en te red  is expected 
to be limited. It is m andatory  that adequate  trials 
on the options and limitations of the use of HGFs
are performed.
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STATEMENT OF ANNOUNCEMENT
Accreditation of programs
Pharmacology
ology
Since that time 240 physicians, clinical pharmacists, and medical scientists have been certified. The process of 
accreditation of programs will formalize the training requirements for Clinical Pharmacology. These requirements 
are detailed in the application for accreditation. Accredited programs must be located at an appropriately accred­
ited institution, and accreditation will provide trainees with a minimum of two years of training in Clinical 
Pharmacology.
Registration of programs
The Board realizes that many institutions do not have all the components of a formal training program
currently in place. For programs that do not meet all requirements, there will be a process by which programs may
register with the Board so that the trainees in the program may be eligible to take the Board examination. Until
the year 2000, programs may register for a five-year period, informing the Board annually of the progress the
program is making toward satisfying the accreditation requirements. Alter that time, the registration period will 
be for a maximum of three (3) years.
After 1997, most candidates for the Board examination will be required to have successfully completed a
fellowship in a registered or a fully accredited program. The Board is prepared to review applications for accred­
itation or registration.
Program directors may obtain information and application forms from the administrative office o f  the
American Board of Clinical Pharmacology, Inc., by writing to: PO Box 40278, San Antonio, TX 78229- 
1278 or bvfax ^210^567-8509 or hv nhnne
